Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib Combined With Cadonilimab in Untreated Advanced RCC
NCT06577961Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of vorolanib and cadonilimab in renal cell carcinoma (RCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 12 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
vorolanibcadonilimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06577961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577961.